Peggy A. Scherle
Chief Scientific OfficerDr. Peggy A. Scherle, Ph.D. has served as Chief Scientific Officer at Prelude Therapeutics Incorporated since April 2018. Dr. Scherle previously held several roles at Incyte Corporation, a pharmaceutical company, most recently as Group Vice President, Discovery Biology and Preclinical Pharmacology from March 2017 until March 2018. Her prior roles at Incyte included Vice President, Preclinical Pharmacology from 2014 until 2017 and as Executive Director, In Vitro Biology from 2011 until 2014. Earlier in her career, Dr. Scherle held scientific research positions with DuPont Pharmaceuticals and Bristol-Myers Squibb. Dr. Scherle received a B.S. degree in Biochemistry from Michigan State University and a Ph.D. in Immunology from the University of Pennsylvania. She completed her postdoctoral training at the National Institutes of Health.
Positions
- Company NamePrelude Therapeutics IncorporatedStock CodePRLDPositionChief Scientific OfficerColleagues
- KVKrishna VaddiFounder, CEO & Director
- PAPaul A. FriedmanIndependent Chairman of the Board
- BDBryant David LimCFO, Chief Legal Officer & Corporate Secretary
- ACAimee CrombieSenior VP and Head of Strategic Planning & Operations
- MPMadhu PudipeddiSenior Vice President of Technical Operations
- DBDavid BonitaIndependent Director
- VSVictor SandorIndependent Director
- KDKatina DortonIndependent Directors
